Examining the Phase 3 BaxHTN Study Results for Baxdrostat in Hard-to-Control and Resistand Hypertension from AstraZeneca

Scheduled for:Dec 30, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A cardiologist or hypertension specialist experienced in managing resistant and uncontrolled hypertension, familiar with aldosterone’s role in blood pressure regulation, and knowledgeable about emerging targeted therapies for cardiometabolic diseases.

Interview Goal

The interview aims to explore the full results of the Phase 3 BaxHTN trial investigating baxdrostat, a first-in-class aldosterone synthase inhibitor, in patients with hard-to-control hypertension. We will examine the clinical impact of the nearly 10 mmHg placebo-adjusted reduction in systolic blood pressure, durability of response, safety outcomes, and baxdrostat’s potential role in reshaping treatment paradigms for resistant and uncontrolled hypertension.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.